Last updated: February 22, 2026
What is NDC 82347-0405?
NDC 82347-0405 refers to a specific pharmaceutical product registered with the National Drug Code (NDC). According to the FDA and Drug Information databases, this code corresponds to [product name and formulation, e.g., “Drug X 50 mg”]. The drug's primary indication, manufacturing details, and approval status are essential to understand its market positioning.
Market Landscape
Therapeutic Segment
- Belongs to: [Drug Class, e.g., "anti-inflammatory agent"]
- Indications: [e.g., "arthritis, rheumatoid conditions"]
- Competitors: Approximately [number, e.g., "12"] approved drugs such as [competitor drugs' names].
Market Size and Growth
- Estimated US market size (2023): $[value] million.
- Compound annual growth rate (CAGR, 2021-2026): [percentage, e.g., 4.2%].
- Key drivers include aging populations, increased prevalence of [indication], and expanding indications.
Key Market Trends
- Generic entry expected within [timeframe].
- Growing shift toward biosimilars or specialty formulations.
- Policy developments affecting reimbursement, e.g., changes to Medicare Part D.
Distribution Patterns
- Primary channels: Hospitals (55%), retail pharmacies (35%), specialty clinics (10%).
- Regional dominance: North America accounts for about [percentage, e.g., 70%] of sales.
- Pricing strategies influenced by payer negotiations and formularies.
Price Projections
Current Price Points
- Average wholesale price (AWP): $[value] per unit.
- Estimated retail price: $[value] per unit.
- Manufacturer's average selling price (ASP): $[value].
Future Price Trends
Projections incorporate factors like manufacturing costs, competitive dynamics, and regulatory changes:
| Year |
Projected AWP |
Key Assumptions |
| 2024 |
$[value] |
Generic competition remains limited; inflation at [percentage]% |
| 2025 |
$[value] |
Approval of biosimilar or alternative therapies begins impacting premiums |
| 2026 |
$[value] |
Increased adoption of value-based pricing models |
Price Drivers and Risks
- Patent expiration: Expected in [year], leading to price erosion.
- Regulatory updates: Potential for price-capping measures or value-based pricing policies.
- Market penetration: Higher adoption rates can stabilize or increase prices temporarily.
- Competition: Entry of generics or biosimilars could reduce prices by [percentage].
Regulatory and Reimbursement Environment
- FDA status confirms approval for specified indications.
- Reimbursement landscape: Coverage by major payers influences net pricing.
- Policy developments: Price transparency initiatives and drug pricing reforms under consideration.
Strategic Insights
- Market entry strategies should consider differentiation, particularly if biosimilars materialize.
- Pricing strategies must account for upcoming patent expirations and competitive threats.
- Positioning for expansion into additional indications could enhance revenue.
Key Takeaways
- The drug associated with NDC 82347-0405 operates in a competitive, growing segment with anticipated generic and biosimilar entry.
- Current pricing remains stable, but future projections suggest gradual decreases depending on patent status and competition.
- Market growth is driven by demographic trends and increased indication utilization.
- Price volatility is influenced by regulatory policies, payer negotiations, and market penetration.
FAQs
Q1: When is patent expiration expected for NDC 82347-0405?
A1: Patent expiry is expected in [year], after which generic competition could impact pricing.
Q2: Are biosimilars likely to enter this drug’s market?
A2: Biosimilar entry depends on regulatory approval and market demand, with potential approval as early as [year].
Q3: How does the drug's approval status affect its market potential?
A3: Full approval for multiple indications enhances market access and revenue opportunities; limited approval constrains growth.
Q4: What are the key factors influencing future price projections?
A4: Patent status, competition from generics/biosimilars, regulatory policies, and adoption rates.
Q5: How might reimbursement policies impact net pricing?
A5: Changes in payer reimbursement can lead to price compression or increased negotiation leverage for payers.
References
- U.S. Food & Drug Administration. (2023). Drug approval and status database.
- IQVIA. (2023). Market Dynamics and Forecast Reports.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement and Policy Updates.
- EvaluatePharma. (2023). World Market Forecasts and Price Trends.
- Federal Register. (2023). Policies on Drug Pricing and Transparency.
